# IGC Pharma, Inc.: Form 10-Q for the period ended Dec 31, 2016

- Company: [IGC Pharma, Inc.](/companies/igc.md) (CIK 1326205)
- Form: 10-Q
- Filed: 2017-02-21
- Accepted by EDGAR: Feb 21, 2017, 16:09 ET
- Period: 2016-12-31
- Accession: 0001185185-17-000430
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1326205/000118518517000430/indiaglobal10q123116.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1326205/000118518517000430/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-10-01 to 2016-12-31 | $250.0k | us-gaap:Revenues |
| Revenue | 9 months, 2016-04-01 to 2016-12-31 | $487.0k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-10-01 to 2016-12-31 | $122.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2016-04-01 to 2016-12-31 | $276.0k | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months, 2016-10-01 to 2016-12-31 | $323.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2016-04-01 to 2016-12-31 | $960.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-10-01 to 2016-12-31 | −$386.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-04-01 to 2016-12-31 | −$1.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-10-01 to 2016-12-31 | $46.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2016-04-01 to 2016-12-31 | $136.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-10-01 to 2016-12-31 | $73.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2016-04-01 to 2016-12-31 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-10-01 to 2016-12-31 | −$111.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-04-01 to 2016-12-31 | −$1.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-10-01 to 2016-12-31 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2016-04-01 to 2016-12-31 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-10-01 to 2016-12-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2016-04-01 to 2016-12-31 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-10-01 to 2016-12-31 | 27,446,095 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2016-04-01 to 2016-12-31 | 27,446,095 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2016-04-01 to 2016-12-31 | −$483.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2016-04-01 to 2016-12-31 | $129.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-12-31 | $744.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-12-31 | $1.8m | us-gaap:AssetsCurrent |
| Total assets | at 2016-12-31 | $11.2m | us-gaap:Assets |
| Current liabilities | at 2016-12-31 | $761.0k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-12-31 | $3.6m | us-gaap:Liabilities |
| Long-term debt | at 2016-12-31 | $446.0k | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2016-12-31 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2016-12-31 | $7.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 13,293 characters.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q, and the Annual Report on Form 10-K filed with the SEC on July 14, 2016. In addition to historical consolidated financial information the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in our Annual Report on Form 10-K filed with the SEC on July 14, 2016, including the risk factors set out in Item 1A therein. Therefore, the financial statements included in this Report should be read in conjunction with the audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on July 14, 2016. All information presented herein is based on the Company’s fiscal calendar. Unless otherwise stated, references to particular years, quarters, months or periods refer to the Company’s fiscal years ended in March and the associated quarters, months and periods of those fiscal years. Each of the terms the “Company” and “IGC” as used herein refers collectively to India Globalization Capital, Inc. and its subsidiaries. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

### Available Information

The Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are filed with the SEC. The Company is subject to the informational requirements of the Exchange Act and files or furnishes reports, proxy statements, and other information with the SEC. Such reports and other information filed by the Company with the SEC are available free of charge on the Company’s website at www.igcinc.us when such reports are available on the SEC’s website. The public may read and copy any materials filed by the Company with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Room 1580, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov. The contents of websites are not incorporated into this filing. Further, the Company’s references to website URLs are intended to be inactive textual references only.

### Company Overview

India Globalization Capital, Inc. (“IGC”), a Maryland corporation, was organized on April 29, 2005 as a blank check company formed for the purpose of acquiring one or more businesses with operations primarily in India, Hong Kong, China and now Malaysia, through a merger, capital stock exchange, asset acquisition or other similar business combination or acquisition. On March 8, 2006, the Company completed an initial public offering. IGC is headquartered in the United States. The operations of IGC are based in USA, India, and Malaysia. In the United States, throughout our research on phytocannabinoid-based therapies, we develop intellectual property for the treatment of life altering or life threatening conditions; for the purpose of leasing, we also build state-of-the art farming facilities. In India, we lease heavy equipment and in Malaysia, we develop manage and sell residential and commercial real estate.

Phytocannabinoids are chemical compounds that exert a range of effects on the human body, including impacting the immune response, gastrointestinal maintenance and motility, muscle functioning, and nervous system response and functioning. We have filed five provisional patents with the United States Patent and Trademark Office (“USPTO”), in the combination therapy space, for the indications of pain, medical refractory epilepsy and cachexia as part of our intellectual property strategy focused on the phytocannabinoid-based health care industry. There is no guarantee that filing a provisional or a non-provisional patent application will result in a successful registration with the USPTO. In addition, when federal laws become more favorable, we intend to build leading edge facilities that we can use to grow, extract, and supply pharmaceutical grade phytocannabinoids.

### Business Strategy

Our short-term plans are to develop, test, and patent phytocannabinoid-based pharmaceutical therapies, build leading edge facilities that can be used to grow and extract pharmaceutical grade phytocannabinoids and develop the hotel complex in Genting Malaysia, while jettisoning our trading business. Our long-term plan is to establish, in the USA, IGC as a leading provider of phytocannabinoid-based pharmaceutical and nutraceutical products.

### List of Subsidiaries

| Subsidiaries | Immediate holding company | Country of Incorporation | Percentage of holding as of December 31, 2016 | Percentage of holding as of March 31, 2016 |
| --- | --- | --- | ---: | ---: |
| H&F Ironman Limited (“HK Ironman”) (1) | IGC | Hong Kong | 100 | 100 |
| Linxi H&F Economic and Trade Co. (“PRC Ironman”) (3) | HK Ironman | Peoples’ Republic of China | 0 | 95 |
| IGC – Mauritius (“IGC-M”) (1) | IGC | Mauritius | 100 | 100 |
| Techni Bharathi Private Limited (“TBL”) (2) | IGC-M | India | 100 | 100 |
| IGC Materials Private Limited (“IGC-MPL”) (2) | IGC-M | India | 100 | 100 |
| IGC International Limited (“IGC-INT”) (4) | IGC | Hong Kong | 0 | 51 |
| Cabaran Ultima Bhd. Sdn. (“Ultima”) (5) | IGC | Malaysia | 100 | 100 |

(1) Wholly-owned by India Globalization Capital, Inc.

(2) Wholly-owned by India Globalization Capital, Mauritius, Limited.

(3) 95% owned by HK Ironman, which is India Globalization Capital, Inc.’s wholly-owned subsidiary.

(4) Formerly known as Golden Gate Electronics Limited.

(5) 100% owned by India Globalization Capital, Inc.

### Results of Operations

### Three Months ended December 31, 2016 Compared to Three Months ended December 31, 2015

*Revenue -* Total revenue was $250 thousand for the three months ended December 31, 2016 as compared to $1,085 thousand for the same period in 2015. In the third quarter ended December 31, 2016 the revenue was primarily generated by the renting of heavy equipment and from managing the construction of the hotel in Genting. The decrease in revenue is primarily due to the curtailing of the electronic trading business in the quarter ended September 30, 2016.

*Cost of Revenue (excluding depreciation) –* Cost of revenue for the three months ended December 31, 2016 was $122 thousand as compared to $879 thousand for the same period in 2015. The decrease in cost of revenue stems from a decrease in the volume of business as reflected in the decrease in revenue.

*Selling, General and Administrative* - Selling, general and administrative expenses was $323 thousand for the three months ended December 31, 2016 as compared to $438 thousand for the same period in 2015. Most of the expenses are public company related expenses.

*Depreciation –* The depreciation expense was approximately $196 thousand in the three months ended December 31, 2016 as compared to $143 thousand in the three months ended December 31, 2015. Most of the depreciation comes from the assets in China.

*Interest and other financial expenses –* The interest expense and other financial expenses for the three months ended December 31, 2016 were approximately $46 thousand as compared to approximately $51 thousand for the same quarter in 2015. Most of the interest is paid with shares of the Company and is therefore non-cash. Other income for the three-month period ended December 31, 2016 includes realization of other comprehensive income from disposal of Ironman, income received from the supply of skilled operators for the heavy equipment rental business and from the rent of the apartment belonging to TBL, which is located in Kochi, India.

*Other Income/(loss) –* Other income was $359 thousand for the three-month period ended December 31, 2016 as compared to a loss of $19 thousand in same period in 2015.

*Consolidated Net Income/(loss) –* In the three months ended December 31, 2016, the Company reported a GAAP net income loss of $111 thousand and a GAAP EPS of $0.00 compared to a GAAP net income loss of $403 thousand and a GAAP EPS loss of $0.02 for the three months ended December 31, 2015.

### Nine Months Ended December 31, 2016 Compared to Nine Months Ended December 31, 2015

*Revenue -* Total revenue was approximately $487 for the nine months ended December 31, 2016, as compared to about $4,999 thousand for the same period in 2015. The decrease in revenue is from our deliberate move away from the electronic trading business in Hong Kong.

*Cost of Revenue (excluding depreciation) –* Cost of revenue for the nine months ended December 31, 2016 was approximately $276 thousand as compared to approximately $4,423 thousand for the same period in 2015.

*Selling, General and Administrative* - Selling, general and administrative expenses were about $960 thousand for the nine months ended December 31, 2016 as compared to approximately $1,268 thousand for the for the same period in 2015.

*Depreciation –* The depreciation expense was approximately $392 thousand in the nine months ended December 31, 2016 as compared to about $448 thousand for the same period in 2015.

*Interest and Other Financial Expenses –* The interest expense and other financial expenses for the nine months ended December 31, 2016 were about $136 thousand as compared to approximately $180 thousand for the same period in 2015.

*Other Income/(loss) –* Other income was $373 thousand for the nine-month period ended December 31, 2016 as compared to a loss of $119 for the same period in 2015.

*Consolidated Net Income/ (loss) –* Consolidated net loss for the nine months ended December 31, 2016 was approximately $1,110 thousand compared to a consolidated net loss of about $1,385 thousand for the nine months ended December 31, 2015.

### Off-Balance Sheet Arrangements

We do not have any undisclosed investments in special purpose entities or undisclosed borrowings or debt.

### Liquidity and Capital Resources

This liquidity and capital resources discussion compares the consolidated company financial position for the nine-month periods ended December 31, 2016 and 2015.

During the nine months ended December 31, 2016, cash used in operating activities was $807 thousand compared to $4 thousand provided during the nine months ended December 31, 2015.

During the nine months ended December 31, 2016, $297 thousand cash was used in investing activities from continuing operations as compared to $35 thousand provided during the same period in 2015.

For the quarter ended December 31, 2016, our non-GAAP cash burn was approximately $204 thousand after adjusting for $196 thousand of depreciation, $32 thousand of non-cash interest expenses and $321 thousand of one time income.

At the end of December 31, 2016, our cash and cash equivalents along with restricted cash was $744 thousand and working capital of $1,076. We currently have sufficient cash to continue business operations with limited expansion.

### Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.

Note 2, “Summary of Significant Accounting Policies” in Part I, Item 1 of this Form 10-Q and in the Notes to Consolidated Financial Statements in Part II, Item 8 of the 2016 Form 10-K, and “Critical Accounting Policies and Estimates” in Part II, Item 7 of the 2016 Form 10-K describe the significant accounting policies and methods used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company’s critical accounting policies and estimates since the 2016 Form 10-K.

## Market risk

As filed, 159 characters.

Pursuant to Item 305(e) of Regulation S-K, the Company is not required to provide the information required by this Item as it is a “smaller reporting company.”

## Controls and procedures

As filed, 1,775 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, management conducted an evaluation, under the supervision and with the participation of its Chief Executive Officer (CEO) and its principal financial and accounting officer (PFAO), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934. Based upon that evaluation, our CEO and PFAO concluded that our disclosure controls and procedures are effective.

Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act as controls and other procedures that are designed to ensure that information required to be disclosed by us in reports filed with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed under the Exchange Act is accumulated and communicated to our management, including our CEO and PFAO, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during our fiscal quarter ended December 31, 2016, which were identified in conjunction with Management’s evaluation required by paragraph (d) of Rule 13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

## Risk factors

As filed, 262 characters.

There are no other risk factors complementing the risk factors previously disclosed in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2016 and in its quarterly report on Form 10-Q for the three-month period ended September 30, 2016.

Filed Feb 21, 2017.
Source: SEC EDGAR, the filing index for accession 0001185185-17-000430. Last ingested by Listed: Nov 6, 2026, 16:27 ET. No prices; not investment advice.
